证券记录 · 已归档季度
ALLO
Allogene Therapeutics, Inc. · Healthcare · Biotechnology
13被追踪持有人
0Δ持有人
69.68M持有股份
$78.74M报告持仓市值
+0新建仓位
−0清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +1.2% · 净新建仓位 0.0% — 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | -4 | 183.62M | $382.24M | +6 | −10 |
| Q1 2026 | 84 | +8 | 106.47M | $259.25M | +11 | −3 |
| Q4 2025 | 76 | +2 | 91.09M | $124.76M | +2 | — |
| Q3 2025 | 16 | 0 | 74.87M | $92.84M | +1 | −1 |
| Q2 2025 | 13 | 0 | 69.68M | $78.74M | — | — |
| Q1 2025 | 10 | +1 | 41.70M | $60.89M | +2 | −1 |
| Q4 2024 | 9 | -2 | 35.46M | $75.54M | — | −2 |
| Q3 2024 | 10 | 0 | 29.49M | $82.58M | — | — |
| Q2 2024 | 10 | — | 28.78M | $67.06M | — | — |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (被动) | 17.90M | — | $20.22M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Capital World Investors ✦ | 11.15M | -9.1% | $12.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 10.25M | +0.5% | $11.59M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 10.25M | +0.5% | $11.59M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | The Vanguard Group ✦ (被动) | 8.26M | — | $9.33M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | The Vanguard Group ✦ (被动) | 8.26M | — | $9.33M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | The Vanguard Group ✦ (被动) | 8.26M | — | $9.33M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | PRIMECAP Management ✦ | 5.72M | +16.0% | $6.46M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 4.03M | -4.2% | $4.56M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 4.03M | -4.2% | $4.56M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 21 | Geode Capital Management ✦ (被动) | 3.79M | +13.0% | $4.29M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | Geode Capital Management ✦ (被动) | 3.79M | +13.0% | $4.29M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 23 | State Street Global Advisors ✦ (被动) | 2.72M | -2.4% | $3.08M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Renaissance Technologies ✦ | 1.67M | +7.3% | $1.89M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 25 | Two Sigma Investments ✦ | 1.61M | -22.3% | $1.82M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 26 | Millennium Management ✦ | 1.50M | +485.1% | $1.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 27 | Fidelity (FMR) ✦ | 983.00K | — | $1.11M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Fidelity (FMR) ✦ | 983.00K | — | $1.11M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 80.62K | +38.5% | $91,105 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 80.62K | +38.5% | $91,105 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 31 | AQR Capital Management ✦ | 80.62K | +38.5% | $91,105 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 32 | AQR Capital Management ✦ | 80.62K | +38.5% | $91,105 | 0.0% | ▲ Add | 2 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 207 持有人, 182.71M 股份, $425.90M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 21
Douglas Earl Martin
Officer · 29.70K 股 · $62,958
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A — Frazier Life Sciences Public Fund, L.P.
Aug 07
SC 13G — STATE STREET CORP
Aug 07
SC 13G/A — Belldegrun Arie
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据